Catechin 3-O-rutinoside



Compound IDCDAMM02246
Common nameCatechin 3-O-rutinoside
IUPAC name2-[[6-[[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-methyloxane-3,4,5-triol
Molecular formulaC27H34O15

Experimental data

Retention time0.39
Adduct[2M+Na]+
Actual mz1219.37
Theoretical mz1219.37
Error0.64
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.1531

Identifiers and class information

Inchi keyPKKUTJOKYCMKKA-YUJJQLKMNA-N
SmilesOC=1C=C(O)C2=C(OC(C3=CC=C(O)C(O)=C3)C(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)C2)C1
SuperclassPhenylpropanoids and polyketides
ClassFlavonoids

Pharmacokinetic properties

Number of descriptor values(#stars)10
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)15
Number of reactive functional groups (#rtvFG)2
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)598.557
Computed dipole moment(dipole)12.726
Total solvent accessible surface area (SASA)883.454
Hydrophobic component of SASA (FOSA)297.389
Hydrophilic component of SASA (FISA)410.117
Pie component of the SASA (PISA)175.948
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1647.64
Number of hydrogen bond donors (donorHB)10
Number of hydrogen bond acceptors (accptHB)20.75
Free energy of solvation of dipole (dip^2/V)0.0982988
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0742736
Globularity descriptor (glob)0.763642
Predicted polarizability in cubic angstroms (QPpolrz)51.833
Predicted hexadecane/gas partition coefficient (QPlogPC16)20.163
Predicted octanol/gas partition coefficient (QPlogPoct)45.213
Predicted water/gas partition coefficient (QPlogPw)37.607
Predicted octanol/water partition coefficient (QPlogPo/w)-2.398
Predicted aqueous solubility (QPlogS)-3.06
Conformation-independent predicted aqueous solubility (CIQPlogS)-3.625
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.196
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)1.279
Predicted brain/blood partition coefficient (QPlogBB)-5.029
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.369
Predicted skin permeability, log Kp (QPlogKp)-7.018
PM3 calculated ionization potential (IP(ev))8.529
PM3 calculated electron affinity (EA(eV))-0.245
Number of likely metabolic reactions (#metab)12
Prediction of binding to human serum albumin (QPlogKhsa)-1.413
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)250.892
Number of nitrogen and oxygen atoms (#NandO)15
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P22748CA4Carbonic anhydrase IVT53378SEA
Q5T7T8COX1Prostaglandin G/H synthase 1T60529SwissTargetPrediction
P20151KLK2Kallikrein 2T01908SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
P60568IL2Interleukin-2T61698SEA
P49763PGFPlacenta growth factorT70792SEA
P04746AMY2APancreatic alpha-amylaseT86918SEA
P14679TYRTyrosinaseT97035SEA
Q9GZQ4NMUR2Neuromedin-U receptor 2T04210SEA
P52209PGD6-phosphogluconate dehydrogenaseT76497SEA
Q16678CYP1B1Cytochrome P450 1B1T92521SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T53378DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P22748CA4
T53378DI0166Glaucoma[ICD-11: 9C61]P22748CA4
T53378DI0372Seborrhoeic dermatitis[ICD-11: EA81]P22748CA4
T60529DI0141Eye anterior segment structural developmental anomaly[ICD-11: LA11]Q5T7T8COX1
T60529DI0145Female pelvic pain[ICD-11: GA34]Q5T7T8COX1
T60529DI0188Hyper-lipoproteinaemia[ICD-11: 5C80]Q5T7T8COX1
T60529DI0207Indeterminate colitis[ICD-11: DD72]Q5T7T8COX1
T60529DI0306Nutritional deficiency[ICD-11: 5B50-5B71]Q5T7T8COX1
T60529DI0320Osteoarthritis[ICD-11: FA00-FA05]Q5T7T8COX1
T60529DI0324Pain[ICD-11: MG30-MG3Z]Q5T7T8COX1
T60529DI0339Postoperative inflammation[ICD-11: 1A00-CA43]Q5T7T8COX1
T60529DI0366Rheumatoid arthritis[ICD-11: FA20]Q5T7T8COX1
T60529DI0372Seborrhoeic dermatitis[ICD-11: EA81]Q5T7T8COX1
T60529DI0416Tuberculosis[ICD-11: 1B10-1B12]Q5T7T8COX1
T60529DI0419Ulcerative colitis[ICD-11: DD71]Q5T7T8COX1
T01908DI0213Innate/adaptive immunodeficiency[ICD-11: 4A00]P20151KLK2
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T70792DI0095Colorectal cancer[ICD-11: 2B91]P49763PGF
T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T76497DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P52209PGD

Copyright © 2025